Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Inclusion criteria

Inclusion Criteria for All Participants (All Groups) Participants must satisfy the following criteria to be enrolled in the study: 1. Participant is ≥ 18 and ≤ 82 years of age at the time of signing the informed consent form (ICF). 2. Participant must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. 3. Participant is able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions, the study visit schedule, and other protocol requirements, including contraception requirements. 4. Participant has a body mass index (BMI) ≥ 18 and ≤ 40 kg/m2 at screening. 5. Participant has a body weight \> 50 kg at screening. 6. Participant is afebrile (febrile is defined as ≥ 38°C or 100.4°F). Inclusion Criteria for Participants with Severe Renal Impairment (RI) - Group 1 Participants in Group 1 must also satisfy the following criteria to be enrolled in the study: 7. Participant has a supine systolic blood pressure (BP) ≥ 90 and ≤ 180 mm Hg, supine diastolic BP ≥ 60 and ≤ 110 mm Hg, and pulse rate ≥ 40 and ≤ 110 beats per minute. 8. Participant has severe renal impairment as defined by an eGFR \< 30 mL/min/1.73 m2 (and not requiring dialysis) at screening. The eGFR will be calculated using the Modification of Diet in Renal Disease (MDRD) equation. 9. Participant must be medically stable for at least 1 month before the first IP administration with a clinically acceptable medical history, physical examination (PE), clinical laboratory safety test results, vital sign measurements, and 12-lead electrocardiograms (ECGs) consistent with the underlying stable RI condition, as judged by the Investigator. a. Participant must have a QTcF value \< 480 ms. 10. Participant must be stable in concomitant medication regimen (defined as not starting a new medication\[s\] or a change in the dosage or frequency of the concomitant medication\[s\] within 7 days or 5 half-lives \[whichever is longer\] before the first IP administration). Inclusion Criteria for Participants with Kidney Failure on IHD - Group 2 Participants in Group 2 must also satisfy the following criteria to be enrolled in the study: 11. Participant has a pulse rate ≥ 40 and ≤ 110 beats per minute. Blood pressure measurements must be consistent with the participant's underlying medical condition(s) and judged by the Investigator as being clinically acceptable for purposes of study entry. 12. Participant must be medically stable for at least 1 month before the first IP administration with a clinically acceptable medical history, PE, clinical laboratory safety test results, vital sign measurements, and 12-lead ECGs consistent with the underlying kidney failure, as judged by the Investigator. 13. Participant must be stable in concomitant medication regimen 14. Participant has been attending an average of 3 hemodialysis treatments per week within the 3 months prior to screening. Inclusion Criteria for Participants with Normal Renal Function -Group 3 15. Participant has a supine systolic BP ≥ 90 and ≤ 160 mm Hg, supine diastolic BP ≥ 50 and ≤ 100 mm Hg, and pulse rate ≥ 40 and ≤ 100 beats per minute. 16. Participant is in good health, as determined by past medical history, PE, vital signs, 12-lead ECG, and clinical laboratory safety test results, and has normal renal function, as defined by having a Clcr \> 90 mL/min estimated using the C-G equation, at screening. 1. If male, participant has a QTcF value \< 470 ms; 2. If female, participant has a QTcF value \< 480 ms. 17. Participant must match at least 1 participant in Groups 1 or 2 with respect to sex, age (approximately ± 10 years), and BMI (approximately ± 30%).